Information intended for UK healthcare professionals only.
The production of this Guidelines card has been commissioned by Novartis Pharmaceuticals UK Ltd. See bottom of page for full disclaimer. Prescribing Information and Adverse Event Reporting can be found here.
1.1 Brolucizumab is recommended as an option for treating wet age-related macular degeneration in adults, only if, in the eye to be treated:
- the best-corrected visual acuity is between 6/12 and 6/96
- there is no permanent structural damage to the central fovea
- the lesion size is less than or equal to 12 disc areas in greatest linear dimension and
- there is recent presumed disease progression (for example, blood vessel growth, as shown by fluorescein angiography, or recent visual acuity changes).
It is recommended only if the company provides brolucizumab according to the commercial arrangement.
1.2 If patients and their clinicians consider brolucizumab to be one of a range of suitable treatments, including aflibercept and ranibizumab, choose the least expensive (taking into account administration costs and commercial arrangements).
1.3 Only continue brolucizumab in people who maintain an adequate response to therapy. Criteria for stopping should include persistent deterioration in visual acuity and identification of anatomical changes in the retina that indicate inadequate response to therapy.
1.4 These recommendations are not intended to affect treatment with brolucizumab that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them.
- NICE. Brolucizumab for treating wet age-related macular degeneration. NICE Technology Appraisal Guidance 672. NICE, February 2021. www.nice.org.uk/guidance/ta672
Brolucizumab has been recommended through the fast track appraisal process, NHS England and commissioning groups have agreed to provide funding to implement this guidance 30 days after publication.
The production and printing of this Guidelines summary card has been commissioned by Novartis Pharmaceuticals UK Ltd. Novartis Pharmaceuticals UK Ltd has reviewed the card for technical accuracy and regulatory compliance and supplied the prescribing information. This summary card only displays the concise guidance; readers are strongly advised to refer to the full guidance at www.nice.org.uk/guidance/ta672.
©NICE 2021 Technology Appraisal 672: Brolucizumab for treating wet age-related macular degeneration. Available from: www.nice.org.uk/guidance/ta672. All rights reserved. Subject to notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this publication.
MGP Ltd owns copyright of the Guidelines brand, logo, and the design and format of this summary card.
The views and opinions expressed are not necessarily those of Novartis Pharmaceuticals UK Ltd, or of Guidelines, its publisher, advisers, or advertisers.
MLR ID 103903
Date of preparation: February 2021